emcardioНеотложная кардиология и кардиоваскулярные рискиEmergency Cardiology and Cardiovascular Risks journal2616-633XБелорусский государственный медицинский университетemcardio-300Research ArticleОригинальные научные публикацииOriginal Scientific ResearchРаспространенность и клиническое значение высокой остаточной реактивности тромбоцитов у пациентов с нестабильной стенокардиейPrevalence and Clinical Significance of high Residual Platelet Reactivity in Patients with Unstable AnginaГелисЛ. Г.GelisL. G.МедведеваЕ. А.MedvedevaE. A.РусскихИ. И.RusskihI. I.Республиканский научно-практический центр «Кардиология»Scientific and Practical Center of Cardiology of the Republic of Belarus201715112025115764Copyright © Гелис Л.Г., Медведева Е.А., Русских И.И., 20252025Гелис Л.Г., Медведева Е.А., Русских И.И.Gelis L.G., Medvedeva E.A., Russkih I.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://emcardio.bsmu.by/jour/article/view/300

Пациенты с НС при разных стратегиях лечения имели достаточно высокий процент выявленной резистентности к антиагрегантам: 1 Г-26,4%, 2Г-45,6%, 3Г- 47%, что в дальнейшем (за 18 месяцев наблюдения) привело к развитию повторных коронарных событий.Сердечно-сосудистые осложнения развились у 38 лиц (29,9%) с НС за 18 месяцев наблюдения, из них у 29 пациентов с высокой остаточной реактивностью тромбоцитов (ВОРТ). Риск развития повторных коронарных событий у лиц с ВОРТ значительно выше, чем у пациентов, чувствительных к антиагрегантам: относительный риск ОР=5,5; доверительный интервал [95%ДИ 2,7-19]; р=0,0001. Выявление одновременной резистентности к клопи-догрелу и ацетилсалициловой кислоте (АСК) выявлено у 6,3% пациентов и связано с высоким риском повторных коронарных событий в течение 18 месяцев наблюдения (r=0,74; р=0,0002), при этом относительный риск составил ОР=8,9 в сравнении с пациентами с хорошей чувствительностью к антиагрегантам; доверительный интервал [95%ДИ 6,7-31]; р=0,0001.

Patients with UA with different treatment strategies had a fairly high percentage of detected resistance to antiplatelet agents: 1G-26,4%, 2G-45,6%, 3G - 47% which in the future (within 18 months of observation)resulted in the development of recurrent coronary events. Cardiovascular complications occurred in 38 individuals (29,9%) with UA within 18 months follow-up, of whom 29 patients had high residual platelet reactivity. The risk of recurrent coronary events in patients with high residual platelet reactivity is significantly higher than in patients sensitive to antiplatelet agents: relative risk RR=5,5; confidence interval [95% CI of 2.7-19]; p=0.0001. Simul¬taneous resistance to clopidogrel and acetylsalicylic acid (ASA) was detected in 6.3% of patients which was associated with a high risk of repeated coronary events within 18 months of observation (r=0.74; p=0.0002), while the relative risk was RR=8.9 in comparison with patients with good sensitivity to antiplatelet agents; confidence interval [95% CI 6,7-31]; p=0.0001.

нестабильная стенокардиястентирование коронарных артерийрезистентность к антиагрегантной терапиипрофилактика повторных коронарных событийunstable anginaresistance to antiplatelet therapystenting of coronary arteriespreven tion of recurren t coronary even tsReferencesVorob'eva I.I., Rizhkova E. V., Vasil'eva E.YU., SHpektor A. V. Vliyanie sistemnogo vospaleniya na effekt antiagregantnoi terapii u bol'nih s ostrim koronarnim sindromom [Influence of systemic inflammation on the effect of antiplatelet therapy in patients with acute coronary syndrome]. Kreativnaya kardiologiya, 2012, no. 1, pp. 5-14. (in Russian).Vorob'eva I.I., Rizhkova E. V., Vasil'eva E.YU., SHpektor A. V. Vliyanie sistemnogo vospaleniya na effekt antiagregantnoi terapii u bol'nih s ostrim koronarnim sindromom [Influence of systemic inflammation on the effect of antiplatelet therapy in patients with acute coronary syndrome]. Kreativnaya kardiologiya, 2012, no. 1, pp. 5-14. (in Russian).Andreev D. A. Rol' testirovaniya funktsional'noi aktivnosti trombotsitov v profilaktike serdechno-sosudistih oslozhnenii u bol'nih, poluchayuschih antitrombotsitarnuyu terapiyu [The role of testing the functional activity of platelets in the prevention of cardiovascular complications in patients receiving antiplatelet therapy]. Ratsional'naya Farmakoterapiya v Kardiologii, 2014, vol. 10, no. 6, pp. 679-687. (in Russian).Andreev D. A. Rol' testirovaniya funktsional'noi aktivnosti trombotsitov v profilaktike serdechno-sosudistih oslozhnenii u bol'nih, poluchayuschih antitrombotsitarnuyu terapiyu [The role of testing the functional activity of platelets in the prevention of cardiovascular complications in patients receiving antiplatelet therapy]. Ratsional'naya Farmakoterapiya v Kardiologii, 2014, vol. 10, no. 6, pp. 679-687. (in Russian).Puchin'yan N.F., Furman N. V., Dolotovskaya P. V., Malinova L. I. Visokaya ostatochnaya reaktivnost' trombotsitov na fone dvoinoi antiagregantnoi terapii, viyavlennaya metodom opticheskoi agregatometrii, i chastota razvitiya aterotromboticheskih oslozhnenii posle stentirovaniya koronarnih arterii u bol'nih ishemicheskoi bolezn'yu serdtsa v real'noi klinicheskoi praktike [High residual reactivity of platelets against a background of dual antiplatelet therapy, revealed by the method of optical aggregation, and the frequency of development of atherothrombotic complications after coronary artery stenting in patients with coronary heart disease in real clinical practice]. Ratsional'naya Farmakoterapiya v Kardiologii, 2016, vol. 12, no. 4, pp. 385-390. (in Russian).Puchin'yan N.F., Furman N. V., Dolotovskaya P. V., Malinova L. I. Visokaya ostatochnaya reaktivnost' trombotsitov na fone dvoinoi antiagregantnoi terapii, viyavlennaya metodom opticheskoi agregatometrii, i chastota razvitiya aterotromboticheskih oslozhnenii posle stentirovaniya koronarnih arterii u bol'nih ishemicheskoi bolezn'yu serdtsa v real'noi klinicheskoi praktike [High residual reactivity of platelets against a background of dual antiplatelet therapy, revealed by the method of optical aggregation, and the frequency of development of atherothrombotic complications after coronary artery stenting in patients with coronary heart disease in real clinical practice]. Ratsional'naya Farmakoterapiya v Kardiologii, 2016, vol. 12, no. 4, pp. 385-390. (in Russian).Straub N., Beivers A., Lenk E., Aradi D., Sibbing D. A model-based analysis of the clinical and economic impact of personalising P2Y12-receptor inhibition with platelet function testing in acute coronary syndrome patients. Thromb. Haemost, 2014, vol. 111, no. 2. pp. 290-299.Straub N., Beivers A., Lenk E., Aradi D., Sibbing D. A model-based analysis of the clinical and economic impact of personalising P2Y12-receptor inhibition with platelet function testing in acute coronary syndrome patients. Thromb. Haemost, 2014, vol. 111, no. 2. pp. 290-299.Price M. J., Berger P. B., Teirstein P. S., Tanguay J. F., Angiolillo D. J., Spriggs D., Puri S., Robbins M., Garratt K. N., Bertrand O. F., Stillabower M. E., Aragon J. R., Kandzari D. E., Stinis C. T., Lee M. S., Manoukian S. V., Cannon C. P., Schork N. J., Topol E. J., GRAVITAS Investigators Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA, 2011, vol. 305, no. 11, pp. 1097-1105.Price M. J., Berger P. B., Teirstein P. S., Tanguay J. F., Angiolillo D. J., Spriggs D., Puri S., Robbins M., Garratt K. N., Bertrand O. F., Stillabower M. E., Aragon J. R., Kandzari D. E., Stinis C. T., Lee M. S., Manoukian S. V., Cannon C. P., Schork N. J., Topol E. J., GRAVITAS Investigators Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA, 2011, vol. 305, no. 11, pp. 1097-1105.Mirzaev K. B., Andreev D. A., Sichev D. A. Otsenka agregatsii trombotsitov v klinicheskoi praktike [Evaluation of platelet aggregation in clinical practice]. Ratsional'naya Farmakoterapiya v Kardiologii, 2015, vol. 11, no. 1, pp. 85-91. (in Russian).Mirzaev K. B., Andreev D. A., Sichev D. A. Otsenka agregatsii trombotsitov v klinicheskoi praktike [Evaluation of platelet aggregation in clinical practice]. Ratsional'naya Farmakoterapiya v Kardiologii, 2015, vol. 11, no. 1, pp. 85-91. (in Russian).Gelis L. G., Medvedeva E. A., Markova I. A., Russkih I. I., Kolyadko M. G. Klinicheskie posledstviya rezistentnosti k antitrombotsitarnim preparatam u lits, perenesshih nestabil'nuyu stenokardiyu [Clinical consequences of resistance to antiplatelet drugs in people who have undergone unstable angina]. Kardiologiya v Belarusi, 2015, vol. 3, no. 40, pp. 78-88. (in Russian).Gelis L. G., Medvedeva E. A., Markova I. A., Russkih I. I., Kolyadko M. G. Klinicheskie posledstviya rezistentnosti k antitrombotsitarnim preparatam u lits, perenesshih nestabil'nuyu stenokardiyu [Clinical consequences of resistance to antiplatelet drugs in people who have undergone unstable angina]. Kardiologiya v Belarusi, 2015, vol. 3, no. 40, pp. 78-88. (in Russian).Sibbing D., Morath T., Braun S., Stegherr J., Mehilli J., Vogt W., Schomig A., Kastrati A., von Beckerath N. Clopidogrel response status assessed with Multiplate point-of-care analysis and the incidence and timing of stent thrombosis over six months following coronary stenting. Thromb. Haemost, 2010, vol. 103, no 1, pp. 151-159.Sibbing D., Morath T., Braun S., Stegherr J., Mehilli J., Vogt W., Schomig A., Kastrati A., von Beckerath N. Clopidogrel response status assessed with Multiplate point-of-care analysis and the incidence and timing of stent thrombosis over six months following coronary stenting. Thromb. Haemost, 2010, vol. 103, no 1, pp. 151-159.

The authors declare that there are no conflicts of interest present.